4-fluorophenylcarbamoylsulfamoyl chloride | 1025910-16-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluorophenylcarbamoylsulfamoyl chloride
• 英文别名: N-[(4-fluorophenyl)carbamoyl]sulfamoyl chloride
• CAS: 1025910-16-0
• 化学式: C₇H₆ClFN₂O₃S
• 分子量: 252.654
• InChiKey: XLZCCDGEQBYCJB-UHFFFAOYSA-N

物化性质

• 密度：
  1.668±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-fluorophenylcarbamoylsulfamoyl chloride 在 aluminum (III) chloride 、 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  一种苯并噻二嗪酮类衍生物，其制备方法和用 途

  摘要：

  本发明提供了具有如式(I)所示结构的化合物及其制备方法。本发明还提供了该类化合物在预防和治疗糖尿病并发症药物中的应用，以及含有这些化合物的药物组合物。本发明的化合物对ALR2抑制活性和ALR1抑制活性具有高选择性，在高糖环境下对细胞有保护作用，化合物在大鼠的体内药物半衰期较长，在血液中浓度较高，其对STZ诱导糖尿病大鼠的坐骨运动神经传导损伤、坐骨感觉神经传导损伤有明显修复作用且效果较好，明显加快了感觉神经纤维A‑fiber和C‑fiber的传导速度，显著降低了大鼠坐骨神经中山梨醇，表现出良好的动物安全性。

  公开号：

  CN107056731B
• 作为产物：
  描述：

  氯磺酰异氰酸酯 、 4-氟苯胺 以 二氯甲烷 为溶剂， 生成 4-fluorophenylcarbamoylsulfamoyl chloride
  参考文献：
  名称：

  N-（取代苯基）-1,2,5-噻二唑烷-2-羧酰胺1,1-二氧化物衍生物的高效一锅合成

  摘要：

  1,2,5-噻二唑烷-1,1-二氧化物羧酰胺衍生物3a-3n是在一锅苯胺，氯磺酰基异氰酸酯和2-氯乙胺盐酸盐中经多组分缩合反应合成的新型杂环化合物，在温和的条件下可用作有用的前体情况。在室温下且反应时间短的情况下，以高原子经济性实现了该反应。在所有情况下，都可以在2小时内以良好的良率获得一系列所需的产品。所有合成的化合物均通过1 H，13 C NMR，MS和HMBC / HSQC光谱进行表征。

  DOI：

  10.1002/jhet.3767

文献信息

• PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US20180127370A1

  公开（公告）日：2018-05-10

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• Synthesis of heterocyclic sulfonylureas
  作者：Werner Löwe、Norbert Matzanke

  DOI：10.1002/jhet.5570330340

  日期：1996.5

  We examined the scope of the previously reported one-pot synthesis [1] of chromone-3-sulfonylureas. Different anilines and heterocyclic amines were thereby reacted with chlorosulfonyl isocyanate-derived chlorosulfonylureas. These were treated with different enaminones and enamines to provide the title compounds.

  我们检查了以前报道的一键合成色酮-3-磺酰脲的范围[1]。由此使不同的苯胺和杂环胺与氯磺酰基异氰酸酯衍生的氯磺酰脲反应。将它们用不同的烯胺酮和烯胺处理以提供标题化合物。
• Phenyl amino piperidine mTORC inhibitors and uses thereof
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US10414727B2

  公开（公告）日：2019-09-17

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• 5′-Alkyl-benzothiadiazides: A New Subgroup of AMPA Receptor Modulators with Improved Affinity
  作者：Dean Phillips、Jennifer Sonnenberg、Amy C Arai、Rishi Vaswani、Peter O Krutzik、Thomas Kleisli、Markus Kessler、Richard Granger、Gary Lynch、A Richard Chamberlin

  DOI：10.1016/s0968-0896(01)00405-9

  日期：2002.5

  AMPA receptors form a major subdivision of the glutamate receptor family that mediates excitatory synaptic transmission in the brain, Currents through AMPA receptors can be up- or down-regulated by compounds that allosterically modulate receptor kinetics through binding sites distinct from that for glutamate. One of those modulators is the benzothiadiazide IDRA-21 which has been reported to enhance synaptic transmission and be effective in behavioral tests, but typically requires threshold concentrations of at least 100 muM to be active in vitro. In this study, new benzothiadiazides were developed with IDRA-21 as lead compound and examined for their potency in modulating AMPA receptor kinetics. A significant increase in drug affinity was obtained by alkyl substitution at the 5'-position of IDRA-21; substitutions at other positions of the benzothiadiazide core generally did not yield a further gain in affinity and in some cases abolished drug binding. The 5'-ethyl derivative exhibited an EC50 value in the order of 22 muM which represents about a 30-fold gain in affinity over that of IDRA-21. The EC50 value is comparable to that of cyclothiazide, the most potent benzothiadiazide drug, but the effects on AMPA receptors differed substantially between these two compounds in that the 5'-ethyl derivative of IDRA-21 greatly increased the binding affinity for receptor agonists whereas cyclothiazide is known to reduce agonist binding. The structure-activity relationships reported here thus offer to provide new insights how receptor kinetics is linked to particular aspects of receptor-drug interactions. (C) 2002 Published by Elsevier Science Ltd.
• Acetic Acid Derivatives of 3,4-Dihydro-2<i>H</i>-1,2,4-benzothiadiazine 1,1-Dioxide as a Novel Class of Potent Aldose Reductase Inhibitors
  作者：Xin Chen、Changjin Zhu、Fan Guo、Xiaowei Qiu、Yanchun Yang、Shuzhen Zhang、Minlan He、Shagufta Parveen、Chaojun Jing、Yan Li、Bing Ma

  DOI：10.1021/jm100962a

  日期：2010.12.9

  A series of novel benzothiadiazine 1,1-dioxide derivatives were synthesized and tested for their inhibitory activity against aldose reductase. Of these derivatives, 17 compounds, having a substituted N2-benzyl group and a N4-acetic acid group on the benzothiadiazine, were found to be potent and selective aldose reductase inhibitors in vitro with IC50 values ranging from 0.032 to 0.975 mu M. 9m proved to be the most active in vitro. The eight top-scoring compounds coming from the in vitro test for ALR2 inhibition activity were then tested in vivo, whereby three derivatives, 9i, 9j, and 9m, demonstrated a significantly preventive effect on sorbitol accumulation in the sciatic nerve in the 5-day streptozotocin-induced diabetic rats in vivo. Structure activity relationship and molecular docking studies highlighted the importance of substitution features of N4-acetic acid group and halogen-substituted N2-benzyl group in the benzothiadiazine scaffold and indicated that substitution with hallogen at C-7 had a remarkably strong effect on ALR2 inhibition potency.